BrightGene Bio-Medical Technology Co., Ltd.
15
10
10
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
20%
3 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
A Study of BGM0504 Tablets in Healthy Chinese Subjects
Role: lead
A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function
Role: lead
Bioequivalence Study of BGM0504 Injection
Role: lead
A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants
Role: lead
A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects
Role: lead
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women
Role: lead
A Study of BGM0504 in Participants With Obesity
Role: lead
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
Role: lead
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects
Role: lead
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects
Role: lead
A Study of BGM0504 in Overweight or Obese Participants
Role: lead
A Study of BGM0504 in Chinese Patients With Type 2 Diabetes
Role: lead
A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects
Role: lead
A Study of BGM0504 in Participants with Type 2 Diabetes
Role: lead
A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
Role: lead
All 15 trials loaded